obeticholic acid

Demise of Intercept’s NASH Program Highlights Safety Hurdles Facing the Space
BioSpace
Mon, 07/31/23 - 10:18 am
Intercept Pharma
NASH
obeticholic acid
Intercept restructures as Ocaliva's NASH hopes dashed again with FDA rejection
Fierce Pharma
Thu, 06/22/23 - 10:46 pm
Intercept Pharma
NASH
Ocaliva
obeticholic acid
FDA
Future of Intercept’s NASH drug in doubt after FDA panel rejection
BioPharma Dive
Sun, 05/21/23 - 10:51 pm
Intercept Pharma
FDA
NASH
obeticholic acid
FDA staff unsure NASH drug’s ‘modest’ benefits outweigh safety risks
BioPharma Dive
Wed, 05/17/23 - 10:57 pm
FDA
NASH
OCA
obeticholic acid
Intercept Pharma
FDA schedules adcomms for Entasis' antimicrobial treatment, Intercept's NASH hopeful
Endpoints
Mon, 03/13/23 - 10:19 am
FDA
Entasis
Intercept Pharma
sulbactam-durlobactam
obeticholic acid
NASH
FDA accepts Intercept’s resubmitted NDA for obeticholic acid
Clinical Trials Arena
Thu, 01/26/23 - 10:51 am
FDA
Intercept Pharma
OCA
obeticholic acid
NASH
By summer solstice, we'll know the fate of Intercept's NASH drug
Endpoints
Thu, 01/19/23 - 09:39 am
Intercept Pharmaceuticals
FDA
NASH
obeticholic acid
OCA
Ocaliva fails NASH trial just as Intercept charts path toward FDA application
Fierce Pharma
Fri, 09/30/22 - 12:31 pm
Intercept Pharma
NASH
obeticholic acid
Ocaliva
clinical trials
FDA
Two years after CRL, Intercept will meet with FDA later this month to discuss new analysis of NASH drug
Endpoints
Thu, 07/7/22 - 10:28 am
Intercept Pharma
OCA
obeticholic acid
FDA
NASH
10 clinical trials to watch in the first half of 2022
BioPharma Dive
Mon, 01/3/22 - 10:46 am
clinical trials
Pfizer
Arena Pharmaceuticals
etrasimod
Sanofi
GSK
vaccines
COVID-19
Roche
gantenerumab
AbbVie
Gilead Sciences
Trodelvy
Karuna Therapeutics
KarXT
Intercept Pharma
obeticholic acid
Allogene
ALLO-501a
Intercept, awaiting needed trial data, pulls its NASH drug application in Europe
BioPharma Dive
Fri, 12/10/21 - 12:00 am
Intercept Pharma
NASH
Europe
obeticholic acid
Intercept CEO lays into FDA after NASH drug rejection
Pharmaforum
Tue, 06/30/20 - 10:32 am
Intercept Pharma
Pharma CEOs
NASH
FDA
obeticholic acid
FDA rejects Intercept’s pitch for NASH as CEO fires back at the agency’s ‘evolving’ guidelines
Endpoints
Mon, 06/29/20 - 10:06 am
Intercept Pharmaceuticals
NASH
FDA
obeticholic acid
Intercept hits regulatory snag at FDA, likely delaying NASH drug’s approval
MedCity News
Fri, 05/22/20 - 10:43 am
Intercept Pharma
obeticholic acid
FDA
NASH
While expected, Intercept's approval delay adds to NASH uncertainty
BioPharma Dive
Sat, 01/18/20 - 07:33 pm
Intercept Pharma
NASH
FDA
obeticholic acid
Intercept's NASH decision delayed by FDA, but don't panic: analysts
Fierce Pharma
Mon, 12/16/19 - 10:31 am
Intercept Pharmaceuticals
NASH
obeticholic acid
FDA
2 NASH drugmakers have wildly different Mondays
Biopharma Dive
Mon, 11/25/19 - 10:11 pm
Intercept Pharmaceuticals
CymaBay Therapeutics
FDA
NASH
seladelpar
obeticholic acid
Intercept aims to triple sales force as it gears up for potential NASH launch
Fierce Pharma
Thu, 11/14/19 - 07:42 pm
Intercept Pharma
hirings
drug reps
NASH
drug launches
Ocaliva
obeticholic acid
Intercept Tries to Outrun Pharma in Race for the Next Blockbuster
Bloomberg
Thu, 04/11/19 - 07:27 pm
liver disease
NASH
Intercept Pharmaceuticals
OCA
obeticholic acid
Intercept Pharma is One Step Closer to Filing for Approval of First NASH Treatment
BioSpace
Tue, 02/19/19 - 10:24 am
NASH
Intercept Pharmaceuticals
obeticholic acid
OCA
clinical trials

Pages